Key facts
- It has raised $1.4M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Hunan Lushan Technology Investment, Aeonmed, Ningle Group, Sunz Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Nuoheda Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuoheda Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuoheda Biotechnology
Manufacturer of plant-derived recombinant protein products focused on biopharmaceutical and cosmetic applications. The company specailises in monoclonal antibodies, industrial enzymes, collagen, antigens and cosmetic raw materials, thereby supporting sustainable biotechnology development and contributing to global carbon emission reduction and human health.
- Sector
- Healthcare
- HQ
- Changsha, China
- Founded
- 2022
- Website
- novomorebio.com/
- Ownership
- Privately Held (backing)
Nuoheda Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuoheda Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuoheda Biotechnology in its N-PORT filings yet. We sweep new filings monthly.